Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Approaches to Reducing Phase II Attrition
Phase II is the critical development stage in which most clinical attrition occurs. This report focuses on approaches to improving R&D productivity in the pharmaceutical and biotechnology industries and considers:
- Leading-edge strategies being pursued to improve success rates of therapeutic candidates in clinical development
- The use of translational medicine studies and early clinical trial protocols designed to reduce Phase II attrition
- Survey results and expert interviews on efforts to improve R&D efficiency.
Pharmaceutical companies have been responding to a combination of major challenges that many commentators call a "perfect storm." It is clear that the high rate of attrition in the drug development process is severely limiting the numbers of high-quality novel drug candidates, especially for innovative drugs that address unmet medical needs. In order to overcome this limitation, the industry must develop strategies that can reduce attrition during Phase II, where most attrition occurs, especially as it continues to drive up the cost of R&D to unsustainable levels.
Approaches to Reducing Phase II Attrition considers examples of leading-edge strategies being pursued to improve target selection and other aspects of drug discovery. These include development of multitargeted therapies, whole-pathway approaches, biology-driven drug discovery, analysis of multigenic complex diseases, and network pharmacology. Strategies for improving early-stage clinical studies are discussed, including the use of Phase 0 and adaptive trials, and employing early proof-of-concept trials. Ways in which some companies have adopted new corporate structures designed to increase innovation or make R&D more "biotech-like" are described.